Browse RCOR1

Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Upon infection by HSV-1, it is partially translocated into the cytoplasm in an HSV-1-dependent manner.
Domain PF01448 ELM2 domain
PF00249 Myb-like DNA-binding domain
Function

Essential component of the BHC complex, a corepressor complex that represses transcription of neuron-specific genes in non-neuronal cells. The BHC complex is recruited at RE1/NRSE sites by REST and acts by deacetylating and demethylating specific sites on histones, thereby acting as a chromatin modifier. In the BHC complex, it serves as a molecular beacon for the recruitment of molecular machinery, including MeCP2 and SUV39H1, that imposes silencing across a chromosomal interval. Plays a central role in demethylation of Lys-4 of histone H3 by promoting demethylase activity of KDM1A on core histones and nucleosomal substrates. It also protects KDM1A from the proteasome. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development and controls hematopoietic differentiation.

> Gene Ontology
 
Biological Process GO:0006476 protein deacetylation
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0016570 histone modification
GO:0016575 histone deacetylation
GO:0035601 protein deacylation
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0070933 histone H4 deacetylation
GO:0098732 macromolecule deacylation
Molecular Function GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003714 transcription corepressor activity
GO:0004407 histone deacetylase activity
GO:0008134 transcription factor binding
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
GO:0019213 deacetylase activity
GO:0033558 protein deacetylase activity
Cellular Component GO:0005667 transcription factor complex
GO:0017053 transcriptional repressor complex
GO:1990391 DNA repair complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-3214815: HDACs deacetylate histones
R-HSA-109582: Hemostasis
Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RCOR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RCOR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 2 Resistant to T-cell proliferation
Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RCOR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.250.33
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4520.748
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1060.916
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0150.945
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0650.97
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0460.983
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0110.977
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0180.991
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0220.99
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3070.732
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0050.41
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.010.893
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RCOR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RCOR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RCOR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RCOR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RCOR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RCOR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RCOR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRCOR1
NameREST corepressor 1
Aliases COREST; KIAA0071; RCOR; REST corepressor; Protein CoREST
Chromosomal Location14q32.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RCOR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.